Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31721-31739

  Iriondo, Oihana ^a   Rábano, Miriam ^a   Domenici, Giacomo ^a   Carlevaris, Onintza ^a   López Ruiz, José Antonio ^b   Zabalza, Ignacio ^c   Berra, Edurne ^a   Vivanco, Maria D M ^a  

^a CIC BIOGUNE   (Spain)

^b Servicio de Radiodiagnostico Preteimagen   (Spain)

^c HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Breast cancer; Estrogen receptor; Hypoxia; PHD3; Stem cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; ESTROGEN RECEPTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHD3 PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; UNCLASSIFIED DRUG; EGLN3 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; STEM CELL EXPANSION; ADULT; APOPTOSIS; BREAST; BREAST TUMOR; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; ANTIGENS, CD24; ANTIGENS, CD44; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84945578492     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5564     Document Type: Article

References (80)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98:10869-10874.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100:8418-8423.
5. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-352.
6. Ali H, Rueda OM, Chin SF, Curtis C, Dunning MJ, Aparicio S and Caldas C. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome biology. 2014; 15:431.
7. Payne SJ, Bowen RL, Jones JL and Wells CA. Predictive markers in breast cancer-the present. Histopathology. 2008; 52:82-90.
8. Simoes BM and Vivanco MD. Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen. Future Oncol. 2011; 7:995-1006.
9. Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, Barredo I, Lopez-Ruiz JA, Zabalza I, Kypta R and Vivanco MD. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014; 6:66-79.
10. Clayton H, Titley I and Vivanco M. Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res. 2004; 297:444-460.
11. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT and Eaves CJ. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med. 2008; 14:1384-1389.
12. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15:907-913.
13. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555-567.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
15. Fillmore CM and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10:R25.
16. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.
17. Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene. 2013; 32:4057-4063.
18. Bertout JA, Patel SA and Simon MC. The impact of O2 availability on human cancer. Nature reviews Cancer. 2008; 8:967-975.
19. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. The Journal of clinical investigation. 2013; 123:3664-3671.
20. Bruick RK and McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294:1337-1340.
21. Huang LE, Gu J, Schau M and Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998; 95:7987-7992.
22. Salceda S and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. The Journal of biological chemistry. 1997; 272:22642-22647.
23. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148:399-408.
24. Peurala E, Koivunen P, Bloigu R, Haapasaari KM and Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2012; 133:179-188.
25. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT and Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009; 15:527-538.
26. Henze AT, Garvalov BK, Seidel S, Cuesta AM, Ritter M, Filatova A, Foss F, Dopeso H, Essmann CL, Maxwell PH, Reifenberger G, Carmeliet P, Acker-Palmer A and Acker T. Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nature communications. 2014; 5:5582.
27. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012; 109:2784-2789.
28. Samanta D, Gilkes DM, Chaturvedi P, Xiang L and Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014.
29. Vaupel P, Schlenger K, Knoop C and Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991; 51:3316-3322.
30. Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB and Landberg G. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-alpha status. Cancer Res. 2013; 73:1420-1433.
31. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA and Lee PW. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem cells. 2011; 29:32-45.
32. Mohyeldin A, Garzon-Muvdi T and Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010; 7:150-161.
33. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB and Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15:501-513.
34. Shao Y and Zhao FQ. Emerging evidence of the physiological role of hypoxia in mammary development and lactation. Journal of animal science and biotechnology. 2014; 5:9.
35. Seagroves TN, Hadsell D, McManaman J, Palmer C, Liao D, McNulty W, Welm B, Wagner KU, Neville M and Johnson RS. HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development. 2003; 130:1713-1724.
36. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, BorresenDale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ and Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS medicine. 2006; 3:e47.
37. Buffa FM, Harris AL, West CM and Miller CJ. Large metaanalysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. British journal of cancer. 2010; 102:428-435.
38. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, Cordenonsi M and Piccolo S. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxiainducible factors. Nature. 2012; 487:380-384.
39. Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber S, Tatli H, Coskun U, Yildiz R, Yaman E and Ozturk B. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. Journal of BUON: official journal of the Balkan Union of Oncology. 2012; 17:663-668.
40. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J and Berra E. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007; 120:1451-1458.
41. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J and Chen EI. Identification of a stemlike cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 2010; 12:R94.
42. Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature. 2014; 508:103-107.
43. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN. Hypoxiainducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast cancer research: BCR. 2012; 14:R6.
44. Simoes BM, Piva M, Iriondo O, Comaills V, Lopez-Ruiz JA, Zabalza I, Mieza JA, Acinas O and Vivanco MD. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat. 2011; 129:23-35.
45. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, et al. Molecular definition of breast tumor heterogeneity. Cancer cell. 2007; 11:259-273.
46. Jung YS, Lee SJ, Yoon MH, Ha NC and Park BJ. Estrogen receptor alpha is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHLdeficient cells under hypoxic conditions. Cell cycle. 2012; 11:4462-4473.
47. Stoner M, Saville B, Wormke M, Dean D, Burghardt R and Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Molecular endocrinology. 2002; 16:2231-2242.
48. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC and Watson PH. Intermittent hypoxia induces proteasomedependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:8720-8727.
49. Yi JM, Kwon HY, Cho JY and Lee YJ. Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. Biochemical and biophysical research communications. 2009; 378:842-846.
50. Ryu K, Park C and Lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochemical and biophysical research communications. 2011; 407:831-836.
51. Lloyd MC, Alfarouk KO, Verduzco D, Bui MM, Gillies RJ, Ibrahim ME, Brown JS and Gatenby RA. Vascular measurements correlate with estrogen receptor status. BMC cancer. 2014; 14:279.
52. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, MartinTrevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D'Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem cell reports. 2014; 2:78-91.
53. Zomer A, Ellenbroek SI, Ritsma L, Beerling E, Vrisekoop N and Van Rheenen J. Intravital imaging of cancer stem cell plasticity in mammary tumors. Stem cells. 2013; 31:602-606.
54. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H and Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A. 2002; 99:7021-7026.
55. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB and Rich JN. Hypoxia inducible factors in cancer stem cells. British journal of cancer. 2010; 102:789-795.
56. Mazumdar J, Hickey MM, Pant DK, Durham AC, SweetCordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC and Keith B. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A. 2010; 107:14182-14187.
57. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, Shima H, Johnson RS, Hirao A, Suematsu M and Suda T. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010; 7:391-402.
58. Zhang H, Li H, Xi HS and Li S. HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012; 119:2595-2607.
59. Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8:299-309.
60. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15:220-231.
61. Kim M, Neinast MD, Frank AP, Sun K, Park J, Zehr JA, Vishvanath L, Morselli E, Amelotte M, Palmer BF, Gupta RK, Scherer PE and Clegg DJ. ERalpha upregulates Phd3 to ameliorate HIF-1 induced fibrosis and inflammation in adipose tissue. Molecular metabolism. 2014; 3:642-651.
62. Su Y, Loos M, Giese N, Hines OJ, Diebold I, Gorlach A, Metzen E, Pastorekova S, Friess H and Buchler P. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. British journal of cancer. 2010; 103:1571-1579.
63. Fu J and Taubman MB. Prolyl hydroxylase EGLN3 regulates skeletal myoblast differentiation through an NFkappaB-dependent pathway. The Journal of biological chemistry. 2010; 285:8927-8935.
64. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, Shirley LA, Joyce D, Lisanti MP, Albanese C and Pestell RG. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 2010; 70:10464-10473.
65. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N and Inoue J. NF-kappaB non-cellautonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nature communications. 2013; 4:2299.
66. Kendellen MF, Bradford JW, Lawrence CL, Clark KS and Baldwin AS. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2014; 33:1297-1305.
67. Wei L, Liu TT, Wang HH, Hong HM, Yu AL, Feng HP and Chang WW. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelialmesenchymal transition and nuclear factor-kappaB. Breast Cancer Res. 2011; 13:R101.
68. Ju JH, Jang K, Lee KM, Kim M, Kim J, Yi JY, Noh DY and Shin I. CD24 enhances DNA damage-induced apoptosis by modulating NF-kappaB signaling in CD44-expressing breast cancer cells. Carcinogenesis. 2011; 32:1474-1483.
69. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17:1253-1270.
70. Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D and Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in gammasecretase inhibitor drug responses. EMBO Mol Med. 2013; 5:1502-1522.
71. Vivanco M. Function follows form: defining mammary stem cells. Sci Transl Med. 2010; 2:31ps22.
72. Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, Thompson AM and Coates PJ. Lack of correlation of stem cell markers in breast cancer stem cells. British journal of cancer. 2014; 110:2063-2071.
73. Vivanco MD, Johnson R, Galante PE, Hanahan D and Yamamoto KR. A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development. Embo J. 1995; 14:2217-2228.
74. Campa VM, Baltziskueta E, Bengoa-Vergniory N, GorronoEtxebarria I, Wesolowski R, Waxman J and Kypta RM. A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFkappaB and androgen receptor signaling in prostate cancer. Oncotarget. 2014; 5:8173-8187.
75. Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES and Lewis BA. Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood. 2012; 120:3756-3763.
76. Richard DE, Berra E, Gothie E, Roux D and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. The Journal of biological chemistry. 1999; 274:32631-32637.
77. Berra E, Benizri E, Ginouves A, Volmat V, Roux D and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003; 22:4082-4090.
78. Elizalde C, Campa VM, Caro M, Schlangen K, Aransay AM, Vivanco M and Kypta RM. Distinct roles for Wnt-4 and Wnt-11 during retinoic acid-induced neuronal differentiation. Stem cells. 2011; 29:141-153.
79. Iriondo O, Rabano M and Vivanco MD. FACS Sorting Mammary Stem Cells. Methods in molecular biology. 2015; 1293:63-72.
80. Bengoa-Vergniory N, Gorroño-Etxebarria I, GonzálezSalazar I and Kypta RM. A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 2014; 32:3196-208.